TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) greater than or equal to 30.0 or lesser than or equal to 40.0 kg/m2~* Stable body weight (less than 5% selfreported change within the last 3 months)~Exclusion Criteria:~* Obesity induced by drug treatment~* Use of approved drugs for weight lowering intervention (e.g. orlistat, sibutramin, rimonabant) within the last 3 months prior to entering trial~* Type 1 or type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lira placebo/Lira 2.4 mg/Lira 3.0 mg (Type: PLACEBO_COMPARATOR): Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
- Lira 1.2 mg/Lira 3.0 mg (Type: EXPERIMENTAL): Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
- Lira 1.8 mg/Lira 3.0 mg (Type: EXPERIMENTAL): Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
- Lira 2.4 mg/Lira 3.0 mg (Type: EXPERIMENTAL): Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
- Liraglutide 3.0 mg (Type: EXPERIMENTAL): Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
- Orlistat (Type: ACTIVE_COMPARATOR): Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Muscle Strength Training in Presbyphonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* must receive a diagnosis of presbyphonia by a trained laryngologist. The diagnosis will be given following a visual examination if the observations are consistent with the characteristics of a presbylarynx, as judged by the laryngologist.~* must be 50 years old and older.~Exclusion Criteria:~* has received voice therapy in the past year~* presents with a vocal fold pathology other than presbyphonia~* has a known neurologic or a progressive neuromuscular disease~* has a medical condition that could be aggravated by the experimental intervention, or any condition judged by the physician (Dr. Halstead) as being unsuitable for RMST.~* has dysarthria or a language disorder~* has a hearing loss that is not adequately managed~* has a cognitive disorder that might affect treatment compliance~* is unable to give informed consent

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inspiratory Muscle Strength Training (Type: EXPERIMENTAL): The participants in the IMST arm will receive, in addition to standard of care voice therapy, inspiratory muscle strength training (IMST).~The IMST intervention will consist of 5 sets of 5 breaths in the inspiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal inspiratory pressure (MIP). MIP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer.
- Expiratory Muscle Strength Training (Type: EXPERIMENTAL): The participants in the EMST arm will receive, in addition to standard of care voice therapy, expiratory muscle strength training (EMST).~The EMST intervention will consist of 5 sets of 5 breaths in the expiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal expiratory pressure (MEP). MEP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer.
- Voice Exercises (Type: ACTIVE_COMPARATOR): The participants in the voice exercises group will receive standard of care voice therapy with a speech language pathologist, once a week during four weeks, plus daily practices.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with unexplained infertility~* Age between 18 - 37 years~* Period of infertility \> 1 year~* Patent Fallopian tubes detected by hysterosalpingography and/or laparoscopy~* Normal basal luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin concentrations~* Normal recent semen analysis (according to World Health Organization criteria)~Exclusion Criteria:~* FSH\> 10 IU/L~* Irregular menstrual cycles~* Polycystic ovary syndrome~* Endometriosis~* Endocrinologic disorders~* Systemic disease contraindicating pregnancy~* Previous IUI cycles~* liver or kidney diseases

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- Extended letrozole regimen (Type: EXPERIMENTAL): None
- Clomiphene citrate regimen (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has been postmenopausal for at least 5 years~* Has taken or is taking alendronate~* Agrees not to use medications for osteoporosis other than what is provided by the study~Exclusion Criteria:~* Has a history or evidence of hip fracture~* Has a history of cancer within 5 years of screening, except certain skin or cervical cancers.~* Has active parathyroid disease~* Has a history of thyroid disease not adequately controlled by medication~* Is taking anti-seizure medication and has abnormal calcium metabolism~* Has received any bisphosphonate other than alendronate for 20% of the last 3 years, or within 3 months of screening

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Odanacatib 50 mg (Type: EXPERIMENTAL): Odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Iron Deficiency Anemia During Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Singleton pregnancy.~2. Gestational age 14-18 weeks.~3. Mild to moderate anemia~4. No associated medical or obstetric complications.~5. Women not already receiving iron therapy.~6. Women accepted to participate in the study.~Exclusion Criteria:~1. Multiple pregnancy~2. Severe anemia~3. Iron hypersensitivity.~4. Liver diseases.~5. Women refuse to participate in the study.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Ferrous bis-glycinate group (Type: ACTIVE_COMPARATOR): The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
- Ferrous glycine sulphate group (Type: ACTIVE_COMPARATOR): The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* locally advanced or metastatic colorectal cancer;~* no previous treatment with chemotherapy for metastatic disease;~* at least one measurable lesion.~Exclusion Criteria:~* radiotherapy to any site within 4 weeks before study;~* untreated brain metastases or primary brain tumors;~* clinically significant cardiovascular disease;~* chronic daily treatment with high dose aspirin (\>325 mg/day);~* other co-existing malignancies or malignancies diagnosed within last 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* newly diagnosed glioblastoma~* World Health Organization (WHO) performance status less than or equal to (\<=2)~* stable or decreasing corticosteroid dose within 5 days prior to randomization~Key Exclusion Criteria:~* evidence of recent hemorrhage on postoperative magnetic resonance imaging (MRI) of brain~* any prior chemotherapy or immunotherapy for glioblastomas and low grade astrocytomas~* any prior radiotherapy to brain~* clinically significant cardiovascular disease~* history of greater than or equal to (\>=) grade 2 hemoptysis within 1 month prior to randomization~* previous centralized screening for Methylguanine-DNA methyltransferase (MGMT) status for enrollment into a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + RT + Temozolomide (Type: EXPERIMENTAL): In the Concurrent Phase participants will receive radiotherapy (RT) in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m\^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab 10 mg/kg IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they receive six 28-day cycle of bevacizumab 10 mg/kg IV q2w and temozolomide 150 to 200 mg/m\^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive bevacizumab 15 mg/kg IV q3w until disease progression/unacceptable toxicity.
- Placebo + RT + Temozolomide (Type: PLACEBO_COMPARATOR): In the Concurrent Phase participants will receive radiotherapy in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m\^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they will receive six 28-day cycle of placebo IV q2w and temozolomide 150 to 200 mg/m\^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive placebo IV q3w until disease progression/unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject completed the preceding trial 243-07-003 (NCT00666965)~Exclusion Criteria:~* Subject discontinued from the preceding trial 243-07-003 (NCT00666965)~* Subject had a serious adverse event which association with the investigational drug is not ruled out during trial 243-07-003~* Subject had a persistent serious adverse event at the baseline, which was observed and association with the investigational drug is ruled out during trial 243-07-003.~* Subject had persistent hallucination or delusion during trial 243-07-003.~* Subject had psychiatric conditions such as confusion, excitation, delirium, abnormal behaviour at the baseline.~* Subject had orthostatic hypotension or a systolic blood pressure (SBP) ≤ 100 mmHg and had a decrease of SBP from spine to standing position ≥ 30 mmHg at baseline.~* Subject had a history of epilepsy, convulsion etc. during trial 243-07-003.~* Subject developed serious ECG abnormality at the baseline.~* Subject had QTc-interval ≥ 500 msec at the baseline or subject had an increase of QTc-interval ≥ 60 msec from the baseline in the trial 243-07-003 and had a QTc-interval \> 470 msec in female or \> 450 msec in male at the baseline.~* Subject had a serum potassium level \< 3.5 mEq/L at the end of the taper period in trial 243-07-003.~* Subject had a total bilirubin ≥ 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or ≥ 100 IU/L) at the end of the period in trial 243-07-003.~* Subject had BUN ≥ 30 mg/dL or serum creatinine ≥ 2.0 mg/dl at the end of the taper period in trial 243-07-003.~* Subject who planned pregnancy during the trial.~* Subject was judged to be inappropriate for this trial by the investigator for the reasons other than above.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- SPM 962 (Type: EXPERIMENTAL): Rotigotine transdermal patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have no previous or present history of a DSM-IV psychiatric or substance dependence disorder within the previous year, according to the Structured Clinical Interview for Diagnosis- DSM-IV (SCID)-Non-Patient Version;~2. Are within 5 years of last menstrual period (LMP);~3. Have a follicular stimulating hormone level (FSH) of 20 IU/ml;~4. Are able to give written informed consent;~5. Must have clear urine toxicology screen upon recruitment;~6. Are fluent in written and spoken English;~7. Are right-handed;~8. Negative urine pregnancy test if still menstruating.~Exclusion Criteria:~1. Mini-mental status exam score of less than or equal to 24;~2. Presence of a psychiatric disorder within previous year or a life time history of ADHD or psychotic disorder including bipolar disorder, schizoaffective disorder, and schizophrenia;~3. Lifetime history of drug addiction or abuse, except nicotine;~4. Regular use of other psychotropic medication;~5. Regular use (more than once a week) of alcohol that is less than 3 drinks/day;~6. Presence of a contraindication to treatment with stimulant medication unless the condition is controlled with medication; this would include the presence of uncontrolled hypertension, coronary disease, atrial fibrillation, and arrhythmia;~7. History of seizures;~8. History of cardiac disease including known cardiac defect or conduction abnormality;~9. Abnormal electrocardiogram during screening;~10. Use of estrogen therapy within previous 2 months;~11. Current pregnancy or planning to become pregnant;~12. Metallic implant;~13. Claustrophobia.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Lisdexamfetamine (Type: ACTIVE_COMPARATOR): Lisdexamfetamine or Vyvanse
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo pill, capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject had symptomatic i.e. burning sensation and/or pain secondary to oral lichen planus.~* Subject had clinically \& histo-pathologically diagnosed as oral lichen planus.~* Subject had not on any treatment for the same or treatment likely to modify their oral lichen planus (e.g. systemic steroids, antifungals, immunosuppressant's, anti-oxidant).~Exclusion Criteria:~* Suffering from any systemic disease/s such as diabetes, hypertension, cardiovascular, respiratory system disease, renal dysfunction, liver disorders, malignancy, active peptic ulcer diseases, acute gastrointestinal diseases, anemia and glaucoma, etc.~* Suffering from serious or recurrent infection, immunodeficiency or HIV.~* Pregnant or breast feeding (including women who wish to be pregnant during the study period).~* Any other mucosal diseases or any other skin diseases which might be associated with oral lesions.~* On any drug therapy which might be causes lichen planus like lesions.~* Known allergy or contraindication to study medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- lycopene group (Type: EXPERIMENTAL): Lycopene- 4 mg capsule by mouth single dose per day for 2 months
- Prednisolone group (Type: ACTIVE_COMPARATOR): Prednisolone- 40 mg capsule by mouth single dose per day for 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Ketamine in Treatment-Resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, 21-65 years;~2. Women of childbearing potential must agree to use a medically accepted means of contraception for the duration of the study;~3. Primary diagnosis of major depressive disorder as assessed by the SCID-P;~4. Current depressive episode;~5. History of a failure to respond to at least one (1) adequate pharmacotherapy trials in the current major depressive episode;~6. Subjects must have scored ≥ 30 on the IDS-C30 at Screening ≥ 24 at Treatment Day #1 and #2;~7. Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document;~8. Subjects must be able to identify a family member, physician, or friend who will participate in the Treatment Contract and serve as an emergency contact.~Exclusion Criteria:~1. Women who plan to become pregnant, are pregnant or are breast-feeding;~2. Any unstable medical illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease;~3. Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG;~4. Lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, OCD, mental retardation, pervasive developmental disorders, or Tourette's syndrome;~5. Drug or alcohol abuse or dependence within the preceding 6 months;~6. Lifetime abuse or dependence on ketamine or phencyclidine;~7. Patients judged by study investigator to be at high risk for suicide.~8. Previous participation in a ketamine study at Mount Sinai

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to this arm will receive intranasal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete